綠葉製藥(02186.HK)注射用蘆比替定在澳門提交新藥上市申請

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

綠葉製藥(02186.HK)注射用蘆比替定在澳門提交新藥上市申請

阿思達克 08-22 03:13

綠葉製藥(02186.HK)公佈，集團由 PharmaMar許可引進的產品注射用蘆比替定「LY01017」已在澳門地區提交新藥上市申請，用於治療接受鉑類藥物化療期間或期後出現疾病進展的複發性SCLC成人患者。

绿叶制药(02186.HK)

Relevant Stocks

绿叶制药(02186.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

綠葉製藥(02186.HK)注射用蘆比替定在澳門提交新藥上市申請

Services

About Us

Agreement Statement